Ionis Pharmaceuticals IONS Ionis Operations — Drug Development Expenses

Similar metrics at other companies

INSMINS1148 — R&D

$10M—

VRTXPharmaceuticals — Development expenses

$756.6M-2.2%

BIIBBIIB080 — Research and development expense

$2.5M—

EXELReportable Segment — Development

$135.72M-11.4%

BIIBSOD1 — Research and development:

$4M-5.9%

INCYReportable Segment — Research and development - internal

$260.18M+13.9%

Questions, answered.

What is Ionis Pharmaceuticals's ionis operations — drug development expenses?

Ionis Pharmaceuticals (IONS) reported ionis operations — drug development expenses of $104.18M in Q1 2026.

How has Ionis Pharmaceuticals's ionis operations — drug development expenses changed year-over-year?

Ionis Pharmaceuticals's ionis operations — drug development expenses decreased by 7.8% year-over-year, from $112.95M to $104.18M.

What is the long-term trend for Ionis Pharmaceuticals's ionis operations — drug development expenses?

Over 3 years (2022 to 2025), Ionis Pharmaceuticals's ionis operations — drug development expenses has grown at a 4.5% compound annual growth rate (CAGR), from $426.23M to $486.2M.

What does ionis operations — drug development expenses mean?

Costs incurred for clinical trials and regulatory activities to advance drug candidates.

How do you interpret ionis operations — drug development expenses?

Higher spending typically indicates an active, late-stage clinical pipeline, while lower spending may indicate pipeline maturity or prioritization.

How does ionis operations — drug development expenses compare across companies?

Comparable to clinical development or late-stage R&D expenses at other pharmaceutical companies.